Published in Metab Brain Dis on September 29, 2015
H3 histamine receptor antagonist pitolisant reverses some subchronic disturbances induced by olanzapine in mice. Metab Brain Dis (2016) 0.75
Serotonergic Control of Metabolic Homeostasis. Front Cell Neurosci (2017) 0.75
The continuing epidemics of obesity and diabetes in the United States. JAMA (2001) 14.84
Long-term drug treatment for obesity: a systematic and clinical review. JAMA (2014) 3.69
The obesity epidemic: pathophysiology and consequences of obesity. Obes Res (2002) 3.04
The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J (2005) 1.56
Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) (2005) 1.52
Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol (2014) 1.52
Association between water consumption and body weight outcomes: a systematic review. Am J Clin Nutr (2013) 1.11
Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther (2007) 1.06
Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats. Br J Pharmacol (2006) 1.02
A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology (2001) 0.99
Thermogenic effects of sibutramine and its metabolites. Br J Pharmacol (1999) 0.99
Effects of chronic fenfluramine administration on hypothalamic neuropeptide mRNA expression. Brain Res (2006) 0.89
Reduced sensitivity to diet-induced obesity in mice carrying a mutant 5-HT6 receptor. Brain Res (2008) 0.88
Targeting 5-HT receptors for the treatment of obesity. Curr Opin Pharmacol (2011) 0.87
Anxiolytic-like and antidepressant-like effects produced by the selective 5-HT6 receptor antagonist SB-258585 after intrahippocampal administration to rats. Behav Pharmacol (2007) 0.86
Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide Y. Br J Pharmacol (2001) 0.84
[Obesity: a review of currently used antiobesity drugs and new compounds in clinical development]. Postepy Hig Med Dosw (Online) (2007) 0.84
Serotonin 1A, 1B, and 7 receptors of the rat medial nucleus accumbens differentially regulate feeding, water intake, and locomotor activity. Pharmacol Biochem Behav (2013) 0.83
Contrasting effects of systemic and central sibutramine administration on the intake of a palatable diet in the rat. Neurosci Lett (2010) 0.82
Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol (2010) 0.82
Partial agonist efficacy of EMD386088, a 5-HT6 receptor ligand, in functional in vitro assays. Pharmacol Rep (2013) 0.81
The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur J Pharmacol (2010) 0.80
Potential role of mirtazapine in underweight older adults. Consult Pharm (2014) 0.80
Antidepressant-like activity of a new piperazine derivative of xanthone in the forced swim test in mice: The involvement of serotonergic system. Pharmacol Rep (2014) 0.83
The role of glutamatergic, GABA-ergic, and cholinergic receptors in depression and antidepressant-like effect. Pharmacol Rep (2015) 0.79
The role of serotonergic, adrenergic and dopaminergic receptors in antidepressant-like effect. Pharmacol Rep (2015) 0.79
H3 histamine receptor antagonist pitolisant reverses some subchronic disturbances induced by olanzapine in mice. Metab Brain Dis (2016) 0.75